Android app on Google Play

Questcor Pharmacueticals (QCOR) Slammed 34% On Reports Aetna Insurance Coverage Dropped

September 19, 2012 10:29 AM EDT Send to a Friend
Get Alerts QCOR Hot Sheet
Price: $80.07 --0%

Rating Summary:
    10 Buy, 6 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 16 | Down: 9 | New: 6
Trade QCOR Now!
Join SI Premium – FREE
Questcor Pharmacueticals, Inc. (NASDAQ: QCOR) is now down 34 percent on reports from Citron Research that Aetna dropped coverage of key drug Acthar.

According to Cintron:
One of the largest managed care providers in the United States, Aetna has disclosed that after studies and review of scientific literature, it finds no proof of efficacy to substantiate reimbursement for Achtar, except for Infantile Spasms (West Syndrome).

Beginning Friday, September 14 Aetna will cease to offer reimbursement for new patients to use HP Acthar Gel, except for the rare indication of infantile spasms.




You May Also Be Interested In


Related Categories

Analyst Comments, Momentum Movers, Trading Halts

Related Entities

Citron Research

Add Your Comment